Lexicon Pharmaceuticals (LXRX) Quarterly Revenue Drop Reinforces Concerns Over Persistent Losses

Lexicon Pharmaceuticals (LXRX) just closed FY 2025 with fourth quarter revenue of US$5.5 million and a basic EPS loss of US$0.04, alongside net income losses of US$15.5 million, keeping the focus squarely on how quickly the top line can scale against persistent red ink. The company has seen quarterly revenue move from US$26.6 million in Q4 2024 to US$5.5 million in Q4 2025, with EPS shifting from a loss of US$0.09 to a loss of US$0.04 over the same periods. Trailing 12 month revenue stands at US$49.8 million against a net loss of US$50.3 million, so margins remain under pressure even as revenue growth forecasts sit at about 27.5% a year. For investors, the story this quarter is about whether that projected revenue pace can start to close the gap between revenue and losses so margins stop compressing.

See our full analysis for Lexicon Pharmaceuticals.

With the latest figures on the table, the next step is to see how these results line up with the prevailing narratives around Lexicon Pharmaceuticals, and where the numbers start to challenge what the market has been assuming.

See what the community is saying about Lexicon Pharmaceuticals

Losses Still Heavy At US$50.3 Million Over The Year

• On a trailing 12 month basis to Q4 2025, Lexicon booked total revenue of US$49.8 million against a net loss of US$50.3 million, so the business is still effectively losing about US$1 for every US$1 of revenue.
• Consensus narrative points to cost cuts and partnerships as a way to improve net margins, yet the trailing loss of US$50.3 million and Basic EPS of US$0.14 loss show that, so far, higher R&D spending and ongoing development work are still keeping the company in loss making territory.
  • Analysts expect revenue to grow by about 11.3% a year over the next 3 years, but also expect Lexicon to remain unprofitable over that period.
  • The expectation that profit margins could eventually move toward the US Pharmaceuticals industry average of roughly 20% sits in clear contrast to the current trailing margin of about 101% loss.

Premium 14.3x P/S Leaves Little Room For Missteps

• Lexicon trades on a P/S of 14.3x compared with 8.9x for peers and 5.2x for the wider US Pharmaceuticals industry, so the market is currently paying a higher multiple of revenue while the company is still loss making.
• Bears argue that paying a premium multiple for a business that is forecast to stay unprofitable raises the bar for future execution, and the recent history of growing losses at roughly 20.7% a year gives that concern some support.
  • Shareholders were diluted over the past year, which ties into bearish worries that further capital raises could be needed if losses stay large.
  • The analyst consensus target of US$3.36 versus the current US$1.68 share price implies upside based on those same forecasts, so any disappointment in revenue growth or margins would directly test that bearish caution.

Skeptics point to the rich 14.3x P/S and continued losses, while bulls focus on the pipeline and revenue potential, so it helps to see how the full bullish case hangs together in one place before taking a view on the stock’s risk or reward profile.🐂 Lexicon Pharmaceuticals Bull Case

Quarterly Swings Highlight Execution Risk Around The Pipeline

• Within FY 2025, quarterly revenue ranged from US$1.3 million in Q1 to US$28.9 million in Q2, with net results moving from a loss of US$25.3 million in Q1 to a profit of US$3.3 million in Q2 and back to a loss of US$15.5 million by Q4, showing earnings still hinge heavily on the timing of milestones and payments.
• Bears highlight that this pattern fits an R&D heavy company that depends on licensing and clinical events, and argue that setbacks across programs like pilavapadin, sotagliflozin and LX9851 could leave these swings skewed toward losses rather than occasional profits.
  • The risk section notes that if late stage trials for cardiometabolic or pain indications slip or fail, revenue tied to those assets could stall while R&D spending continues.
  • With revenue forecast to grow at about 27.5% a year but profitability still out of reach over at least 3 years, the uneven quarterly profile backs the cautious view that execution on the pipeline is central to any long term improvement.

After seeing how lumpy revenue and earnings still are, it is worth checking how detailed the more cautious investors get about trial risks, capital needs and long term earnings power before deciding how much downside you are comfortable with.🐻 Lexicon Pharmaceuticals Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Lexicon Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you’ll be alerted when the story evolves.

If the mixed signals around growth and losses leave you unsure, act quickly and consider the trade off between the potential upside and the risks, starting with the 1 key reward and 2 important warning signs.

Explore Alternatives

Lexicon Pharmaceuticals combines heavy annual losses of US$50.3 million, a rich 14.3x P/S multiple and lumpy revenue. This leaves execution risk firmly on your shoulders.

If that mix of premium pricing, weak profitability and uncertainty feels uncomfortable, shift your focus toward companies screened as having 72 resilient stocks with low risk scores so your portfolio leans more on resilience and less on speculation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com